antiviral news

The fight against infections and Pharmamar initiate a phase II clinical trial to evaluate plitidepsin in the treatment of persistent covid in adults

A new clinical trial shows promising results for an inhaled treatment, MIR 19, in reducing the severity of COVID-19.

Molnupiravir for treating COVID-19 (TA1056).

This new article publication from Acta Pharmaceutica Sinica B, discusses a retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years.

Numerous treatment options for COVID-19 have been approved by the U.S. Food and Drug Administration over the last four years, including antiviral drugs and monoclonal antibodies that suppress an excessive immune response. Now, research from the Keck School of Medicine of USC has found that COVID-19 therapies cause few serious side effects, based on an evaluation of the full spectrum of evidence available from U.S. biomedical science.

Numerous treatment options for COVID-19 have been approved by the U.S. Food and Drug Administration over the last four years, including antiviral drugs and monoclonal antibodies that suppress an excessive immune response.